

**Immune Competence Restoration after Therapy with
Imidocarb Dipropionate and Doxycycline in Dogs
Naturally Infected with *Anaplasma Phagocytophilum*,
Agent of Canine Granulocytic Anaplasmosis,
in Dubai, United Arab Emirates**

May Vanneza Pico (DVM) and Walter Tarello (DVM)*

Pet Connection Veterinary Hospital, Al Barsha 1, Dubai, UAE

*corresponding author

Copyright © 2013 May Vanneza Pico and Walter Tarello. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Canine granulocytic anaplasmosis is a tick-borne zoonotic disease caused by the obligate intracellular bacterium *Anaplasma phagocytophilum* that infect myeloid cells, primary neutrophils, of the host, including humans, dogs and many wildlife species. Anaplasmosis is often described as an immuno-suppressive condition characterized by leucopenia, neutropenia, lymphopenia, thrombocytopenia and non regenerative anemia that predispose to secondary infections. However, the level of such alterations and the type of associated secondary infections are rarely mentioned in literature. In order to provide numerical data on the condition we evaluated the presence and severity of secondary conditions and the degree of leucopenia, neutropenia, lymphopenia, thrombocytopenia and anemia recognizable in 15 cases of

canine anaplasmosis observed in Dubai. Cellular immune-suppression was seen in all cases. Specific therapy for anaplasmosis, including 4 weekly injections of imidocarb dipropionate and a daily administration of 10 mg/kg of doxycycline for 21 days, was capable to restore the immune competence within 3 weeks, confirming that immune-suppression was due to anaplasmosis only. Secondary conditions noticed more often were demodicosis, ringworm and *Malassezia* yeast infection. Therapy for anaplasmosis significantly helped their elimination. In this presentation, we produce numeric data on the immunological defects expressed by canine anaplasmosis by using its specific therapy as a probe.

Keywords: dog - *Anaplasma phagocytophilum* – canine granulocytic anaplasmosis – zoonosis – cellular immune-suppression – anemia – leucopenia – neutropenia – lymphopenia - thrombocytopenia - imidocarb dipropionate – doxycycline – Dubai

INTRODUCTION

Canine granulocytic anaplasmosis is a worldwide distributed Ixodid tick-borne disease caused by the Gram negative intracellular obligate zoonotic bacterium *Anaplasma phagocytophilum* [9]. It is the most widespread tick-borne infection in animals in Europe [27], the 3rd most common vector-borne infection in humans in the U.S. and Europe [9] and an emerging pathogenic condition of concern in China [34].

Originally recognized as the agent of tick-borne fever (TBF) in cattle, the condition was first described in 1932 in Scotland [33]. Then came the discovery of a similar disease in horses in the USA in 1969, followed by the description of two distinct granulocytic agents causing similar diseases in dogs in the USA in 1971 and 1982, *Ehrlichia ewingii* and the agent of canine granulocytic ehrlichiosis (CGE), today known as canine granulocytic anaplasmosis (CGA), *Anaplasma phagocytophilum* [5, 33]. In 1994 the disease was discovered in humans as well [33].

Many species of wild and domesticated animals are susceptible, however clinical manifestations are species-dependant, with humans [9], horses [8], cattle [33] cats [1, 4, 29] and dogs [6, 11, 13, 16, 20, 26, 28, 30] showing mild to severe clinical signs. The incubation period is 1 to 2 weeks in dogs [5, 26]. Many healthy dogs have antibodies to *A. phagocytophilum*, suggesting that mild or subclinical infections are common [25]. Antibodies to *A. phagocytophilum* were found in 563 (50.1%) of 1124 dogs in Germany suspected of having anaplasmosis and tested by an indirect

immunofluorescence test (IFT) [3]. In another study from Germany 43% of 522 dogs, 50% healthy and 50% diseased, resulted seropositive for *Anaplasma phagocytophilum* [16].

Epidemiological surveys indicate a high prevalence of *Anaplasma phagocytophilum* in Italian hunting dogs (14.8%) [10], in pet dogs from Tunisia (25.2%) [21] and stray dogs from Jordan (39.5%) [24].

Anaplasma phagocytophilum was detected in 7.11% of 253 dogs from Brazil by PCR [25].

Among wildlife, there is molecular and/or serological evidence of infection in deer, moose (*Alces alces*) and other cervids, chamois (*Rupicapra rupicapra*), European bison (*Bison bonasus*), mountain lions (*Puma concolor*), Eurasian lynx (*Lynx lynx*), bears [32], red foxes, wild boar (*Sus scrofa*), raccoons, opossums, striped skunks (*Mephitis mephitis*), hares (*Lepus capensis*), rodents [14] and birds [7, 19]. Livestock and wild ungulates, as well as wild rodents, might be reservoir hosts in Europe [27].

Diagnosis of CGA is based on light-microscopy detection of characteristic clusters of bacteria, named elementary bodies and morulae, within neutrophils in blood smears stained with Wright, Giemsa or Diff-Quick, or the combination of acute and convalescent serology using immune-fluorescent antibody tests (IFA) and/or detection of the DNA of *A. phagocytophilum* using specific polymerase chain reaction assays [5]. When serology and PCR are not readily available, the search for inclusions in neutrophils by microscopy is a quick method that confirms the diagnosis [28-30]. Bacteria appear as stippled dark blue or purple inclusions detectable in 20-80% of clinical cases in the acute phase of the disease [2, 33]. Evocative hematologic abnormalities and a positive response to treatment further support the diagnosis [28, 30]. The main preventive measure is tick control [5].

The drug of choice is doxycycline (10 mg/kg body weight daily) for at least 3 weeks. Usually there is a dramatic clinical improvement within 24-48 hours [11]. The efficacy of treatment is faster in dogs simultaneously treated with imidocarb dipropionate [28] and the healing process is quicker when concurrent secondary conditions are simultaneously eliminated [31]. Previously eradicated infections do not confer lifelong immunity, and dogs can become infected with the same bacterium after re-exposure to infective ticks [22].

Lethargy, fever, poor appetite, poly-arthritis (lameness, joint pain), conjunctivitis, cough, vomiting, diarrhea and hemorrhagic signs are the most frequently reported symptoms in canine granulocytic anaplasmosis, with fatal outcomes apparently being rare [6, 11, 15, 18, 20, 21, 28, 30].

Laboratory abnormalities include anemia, leucopenia, neutropenia, lymphopenia, thrombocytopenia and mildly elevated levels of hepatic enzymes in the serum of some dogs [11, 13, 15, 20, 26]. It is widely accepted that anaplasmosis is an immune-pathologic disease that induce leucopenia, characterized by neutropenia or lymphocytopenia [13, 26, 33] and that some clinical signs are caused by opportunistic infections associated with *A. phagocytophilum*-mediated immune suppression [9].

However, reports on the incidence and severity of the hematological anomalies and on the associated opportunistic infections observed in dogs diagnosed with *Anaplasma phagocytophilum* are hard to find in literature.

Therefore, we thought it was worthy to retrospectively review the medical records of 15 consecutive CGA cases observed between 2010 and 2013 in Dubai, United Arab Emirates, and to report the hematological anomalies, clinical signs, concurrent opportunistic conditions and outcomes of therapy in order to expand the current knowledge of the condition.

MATERIAL AND METHODS

Medical records of 15 dogs microscopically diagnosed with *Anaplasma phagocytophilum* between 2010 and 2013 were reviewed retrospectively.

Fresh blood smears from each patient were stained with Wright modified technique and examined with a Leica microscope at day 1 and at day 22.

Hematology was carried out immediately after blood sampling in EDTA at day 1 and day 22 using an in-house Idexx VetTest Laser Cyte.

RESULTS

Signalment, clinical signs and associated conditions are listed in Table 1. Male (10/15) were prevalent over females (5/15). Median age was 4 years. Clinical signs commonly observed were lethargy (6/15), fever (5/15), limping (4/15), vomiting (3/15) and hemorrhagic signs (2/15). Tick infestation was seen in 3/15 cases. Dark blue or purple inclusions bodies were microscopically detected in neutrophils at day 1 but not at day 22. Percentage was not recorded. Associated diseases were adult-onset generalized demodicosis (5/15), ringworm (3/15), pyoderma (2/15) and *Malassezia* yeast dermatitis (2/2).

In Table 2 are showed the laboratory abnormalities, including anemia (10/15, 66%), leucopenia (13/15, 86.6%), neutropenia (15/15, 100%), lymphopenia (10/15, 66%), and thrombocytopenia (13/15, 86.6%), observed at day 1 before therapy (B.T.) and the immune restoration seen at day 22, after therapy (A.T.) when all values were normalized.

DISCUSSION

In these authors' knowledge, reported results are noteworthy for 3 main reasons: the constant detection of neutropenia (Table 2), the complete hematological recovery seen after the end of therapy in all cases (Table 2) and the identification of adult-onset generalized demodicosis, ringworm and *Malassezia* yeast as opportunistic infections in 7/15 cases (Table 1).

It is interesting that neutropenia was present in all CGA cases (15/15, 100%), either in association with lymphopenia (9/15, 60%) or alone, confirming neutropenia as the 'hallmark of infection with CGA that plausibly reflects direct pathogen-mediated cytolytic injury'... 'since *A. phagocytophilum* infects almost exclusively neutrophils in vivo.' [9].

Traditionally, canine granulocytic anaplasmosis has been more often associated with lymphopenia [5, 6, 18] thrombocytopenia [11, 20, 26] and anemia [9]. Recently, a timber wolf with CGA was diagnosed with thrombocytopenia, lymphopenia and anemia but not neutropenia [17]. The present study does not contradict such observations since 10/15 (66%) patients were lymphopenic and 13/15 were thrombocytopenic (86.6%).

However, the dominant feature in this study was neutropenia, a direct indicator of cellular immune-suppression which is often reported in literature in ruminants with tick-borne fever (TBF) and humans with granulocytic anaplasmosis [33]. Leukopenia with neutropenia but not lymphopenia was observed recently in an infected puppy in the USA [13].

Manifestation of hematological anomalies can vary in tick-borne infections, considering that many strains of *A. phagocytophilum* exist [9].

These authors couldn't retrieve a series or a collection of CGA cases in literature reporting the severity of neutropenia observed in dogs. It was thus worthy to submit the data obtained from 15 cases examined in Dubai, showing neutropenia ranging

from 40 to 1990 neutrophils per microliter. Remarkably, all hematological defects were eliminated at day 22, concurrently with clinical recovery, confirming restoration of the immune competence in all cases.

Clinical signs observed in this retrospective analysis (table 1) are compatible with those recorded in previous canine studies [6, 11, 15, 18, 20, 21, 28, 30] with lethargy (6/15), fever (5/15), limping (4/15), vomiting (3/15) and hemorrhagic signs (2/15) reported more often.

Curiously, dog n. 10 had 3 epilepsy-like seizures during the month before consultation that disappeared after therapy (6 months follow-up confirmed the complete recovery). Neurological syndromes, fits and seizures are occasionally described in literature on anaplasmosis [5]. However, this is the first case in which seizures reportedly disappeared after therapy for anaplasmosis in our knowledge.

Because of the severe hematological disorders and other adverse effects on the host's immune functions, animals and humans infected with anaplasmosis are said to be more susceptible to other infections [33].

Opportunistic infections are considered the result of impaired neutrophilic function or leucopenia [9] and are frequently mentioned but rarely tackled in literature on canine granulocytic anaplasmosis.

Anaplasma phagocytophilum seems to favor subcutaneous dirofilariasis caused by the nematode *Dirofilaria repens*, for instance [31]. In a review article on dermatitis associated with *Dirofilaria repens* in dogs authored by one of us (W. Tarello) 40/100 cases observed between 1990 and 2010 appeared to be co-infected with granulocytic ehrlichiosis (anaplasmosis) and therapy for anaplasmosis greatly contributed to the clinical resolution of subcutaneous dirofilariasis [31].

In a study from Germany, Pingen and colleagues observed that 12% of dogs imported from Hungary carried *D. repens* microfilariae and 11.6% were infected with *A. phagocytophilum* [23].

It is interesting to observe that, apart from pyoderma, diseases found associated with canine anaplasmosis in this case series are all conditions considered opportunistic in dogs. Adult-onset generalized demodicosis was the most common (5/15, 33%) followed by ringworm (3/15, 20%) and *Malassezia* yeast dermatitis (2/2, 13.3%).

Demodicosis is a severe parasitic cutaneous disease of dogs caused by the uncontrolled proliferation of demodectic mites belonging to the genus *Demodex* sp. (Acari, Prostigmata) in presence of concomitant factors potentially immune-suppressive, including diabetes, hypothyroidism and granulocytic ehrlichiosis (anaplasmosis) in dogs [30].

In a previous study, among the underlying conditions associated with 12 cases of adult-onset generalized demodicosis refractory or incompletely responding to therapy, one of us (W. Tarello) recorded 8 cases of canine granulocytic ehrlichiosis (anaplasmosis) and surprisingly observed that therapy for anaplasmosis helped the remission of clinical signs of demodicosis, apparently confirming, with the use of the specific therapy as a probe, that the elimination of underlying immune suppressive agents can control the proliferation of *Demodex* mites [30]. Therefore, it should not be controversial to include demodicosis among the pathogens triggered by canine granulocytic anaplasmosis and, moreover, take into consideration ringworm and *Malassezia* as suitable candidates for the same position.

Reported cases were diagnosed in Dubai between 2010 and 2013 in both imported and locally raised dogs. No previous study was carried out in the United Arab Emirates on the presence and prevalence of anaplasmosis in dogs and unfortunately PCR and serology testing are not available locally.

We hope that the Central Veterinary Research Laboratory of Dubai will provide soon such an invaluable service. This is apparently the second study on canine anaplasmosis from the Middle East, though.

One epidemiological survey on stray dogs from Jordan reporting 39.5% prevalence was published in 2012 [24]. Canine anaplasmosis seems quite prevalent in the Middle East. Further studies are needed to assess its prevalence among pet dogs in Dubai and the United Arab Emirates.

ACKNOWLEDGMENTS

The authors thank the staff and management of Pet Connection Veterinary Hospital for the support and continuous help provided during this study.

REFERENCES

- [1] L. Adaszek, M. Górna, M. Skrzypczak, K. Buczek, I. Balicki and S. Winiarczyk, Three clinical cases of *Anaplasma phagocytophilum* infection in cats in Poland, *Journal of Feline Medicine and Surgery*, 15 (2013), 333-337.
- [2] J.S. Bakken and J.S. Dumler, Clinical diagnosis and treatment of human granulocytic anaplasmosis, *Annals of New York Academy of Science*, 1078 (2006), 236-247.
- [3] A. Barutzki, A. De Nicola, M. Zeziola and M. Reule, Seroprevalence of *Anaplasma phagocytophilum* infection in dogs in Germany (in German), *Berliner und Munchner Tierärztliche Wochenschrift*, 119 (2006), 342-347.
- [4] A. Bjoersdorff, L. Svendenius, J.H. Owens and R.F. Massung, Feline granulocytic ehrlichiosis -- a report of a new clinical entity and characterization of the infectious agent, *Journal of Small Animal Practice*, 40 (1999), 20-24.
- [5] D.D. Carrade, J.E. Foley, D.L. Borjesson and J.E. Sykes, Canine granulocytic anaplasmosis: a review, *Journal of Veterinary Internal Medicine*, 23 (2009), 1129-1141.
- [6] K.R. Cockwill, S.M. Taylor, E.C.R. Snead, R. Dickinson, K. Cosford, S. Malek, L.R. Lindsay and P.P. Vissotto de Paiva Diniz, Granulocytic anaplasmosis in three dogs from Saskatoon, Saskatchewan, *Canadian Veterinary Journal*, 50 (2009), 835-840.
- [7] T.J. Daniels, G.R. Battaly, D. Liveris, R.C. Falco and I. Schwartz, Avian reservoirs of the agent of human granulocytic ehrlichiosis? *Emerging Infectious Diseases*, 8 (2002), 1524-1525.
- [8] R.S. Davies, J.E. Madigan, E. Hodzic, D.L. Borjesson and J.S. Dumler, Dexamethasone-induced cytokine changes associated with Diminished disease severity in horses infected with *Anaplasma phagocytophilum*, *Clinical and Vaccine Immunology*, 18 (2011), 1962-1968.
- [9] J.S. Dumler, The biological basis of severe outcomes in *Anaplasma phagocytophilum* infection, *FEMS Immunology and Medical Microbiology*, 64 (2012), 13-20.

- [10] V.V. Ebani, F. Bertelloni, B. Turchi and D. Cerri, Serological and molecular survey and *Anaplasma phagocytophilum* in Italian hunting dogs, *Annals of Agricultural and Environmental Medicine*, 20 (2013), 289-292.
- [11] J.L. Granick, P.J. Armstrong and J.B. Bender, *Anaplasma phagocytophilum* infection in dogs: 24 cases (2000-2007), *Journal of American Veterinary Medical Association*, 234 (2009), 1559-1565.
- [12] J. Jensen, D. Simon, H. Murua Escobar, J.T. Soller, J. Bullerdiek, P. Beelitz, K. Pfister and I. Nolte, *Anaplasma phagocytophilum* in dogs in Germany, *Zoonoses and Public Health*, 54 (2007), 94-101.
- [13] A. Kane, G. Block and L.A. Heeb, An unusual presentation of granulocytic anaplasmosis in a young dog, *Journal of the American Animal Hospital Association*, 47 (2011), 276-279.
- [14] F. Keesing, M.H. Hersh, M. Tibbetts, D.J. McHenry, S. Duerr, J. Brunner, M. Killilea, K. Logiudice, K.A. Schmidt and R.S. Ostfeld, Reservoir competence of vertebrate hosts for *Anaplasma phagocytophilum*, *Emerging Infectious Diseases*, 18(2012), 2013-2016.
- [15] B. Kohn, D. Galke, P. Beelitz and K. Pfister, Clinical features of canine granulocytic anaplasmosis in 18 naturally infected dogs, *Journal of Veterinary Internal Medicine*, 22 (2008), 1289-1295.
- [16] B.Kohn, C. Silaghi, D. Galke, G. Arndt and K. Pfister, Infection with *Anaplasma phagocytophilum* in dogs in Germany, *Research in Veterinary Science*, 91 (2011), 71-76.
- [17] M. Leschnik, G. Kirtz, Z. Virányi, W. Wille-Piazzai and G. Duscher. Acute granulocytic anaplasmosis in a captive timber wolf (*Canis lupus occidentalis*), *Journal of Zoo and Wildlife Medicine*, 9 (2012), 645-648.
- [18] S.J. Lester, E.B. Breitschwerdt, C.D. Collins and B.C. Hegarty, *Anaplasma phagocytophilum* infection (granulocytic anaplasmosis) in a dog from Vancouver Island, *Canadian Veterinary Journal*, 46 (2005), 825-827.
- [19] R. Z. Machado, M.R. André, K. Werther, E. de Sousa, F.A. Gavioli and J.R. Junior Alves, Migratory and carnivorous birds in Brazil: reservoirs for *Anaplasma* and *Ehrlichia* species? *Vector-Borne and Zoonotic Diseases*, 12 (2012), 705-708.

- [20] A.W. Mazepa, L.B. Kidd, K.M. Young and L.A. Trepanier, Clinical presentation of 26 *Anaplasma phagocytophilum*-seropositive dogs residing in an endemic area, *Journal of the American Animal Hospital Association*, 46 (2010), 405-412.
- [21] Y. M'ghirbi, A. Ghorbel, M. Amouri, A. Nebaoui, S. Haddad and A. Bouattour, Clinical, serological, and molecular evidence of ehrlichiosis and anaplasmosis in dogs in Tunisia, *Parasitol Res.*, 104 (2009), 767-774.
- [22] T.M. Neer, E.B. Breitschwerdt, R.T. Greene and M.R. Lappin, Consensus statement on ehrlichial diseases of small animals from the Infectious Disease Study Group of the ACVIM, *Journal of Veterinary Internal Medicine*, 16 (2002), 309-315.
- [23] C.H. Pingen, S. Lorenz, J. Magnis, B. Menn R. Schaper and T.J. Nauche, Successful treatment of *Dirofilaria repens* infections in dogs with melarsomine (Immiticide, Merial) against adults and a combination of moxidectin 2.5%/imidacloprid 10% (Advocate, Bayer) against microfilaria, *Proceedings of the 8th International Conference of the World Association for the advancement of Veterinary Parasitology (WAAP '09)*, Alberta, Canada, August 2009.
- [24] M.A. Qablan, M. Kubelova, P. Siroky, D. Modry and Z.S. Amr, Stray dogs of northern Jordan as reservoirs of ticks and tick-borne hemopathogens, *Parasitology Research*, 111 (2012), 301-307.
- [25] H.A. Santos, M.S. Pires, J.A. Vilela, T.M. Santos, J.L. Faccini, C.D. Baldani, S.M. Thome', A. Sanavria and C.L. Massard, Detection of *Anaplasma phagocytophilum* in Brazilian dogs by real-time polymerase chain reaction, *Journal of Veterinary Diagnostic Investigation*, 23 (2011), 770-774.
- [26] D.G. Scorpio, J.S. Dumler, N.C. Barat, J.A. Cook, C.E. Barat, B.A. Stillman, K.C. DeBisceglie and M.J. Beall, Comparative strain analysis of *Anaplasma phagocytophilum* infection and clinical outcomes in a canine model of granulocytic anaplasmosis, *Vector-Borne and Zoonotic Diseases*, 11 (2011), 223-229.
- [27] S. Stuen, *Anaplasma phagocytophilum* - the most widespread tick-borne infection in animals in Europe, *Veterinary Research Communications*, Suppl 1 (2007), 79-84.
- [28] W. Tarello, Canine granulocytic ehrlichiosis (CGE) in Italy, *Acta Veterinaria Hungarica*, 51 (2003), 73-90.

[29] W. Tarello, Microscopic and clinical evidence for *Anaplasma (Ehrlichia) phagocytophilum* infection in Italian cats, *Veterinary Record*, 156 (2005), 772-774.

[30] W. Tarello, Remission of clinical signs of adult-onset generalized demodicosis after treatment in dogs for concurrent babesiosis and/or granulocytic ehrlichiosis in dogs, *Parasite*, 14 (2007), 339-341.

[31] W. Tarello, Clinical aspects of dermatitis associated with *Dirofilaria repens* in pets: a review of 100 canine and 31 feline cases (1990-2010) and a report of a new clinic case imported from Italy to Dubai, *Journal of Parasitology Research*, volume 2011, article ID 578385, Free online access.

[32] B. Víchová, V. Majláthová, M. Nováková, M. Straka and B. Pet'ko, First molecular detection of *Anaplasma phagocytophilum* in European brown bear (*Ursus arctos*), *Vector-Borne and Zoonotic Diseases*, 10 (2010), 543-545.

[33] Z. Woldehiwet, The natural history of *Anaplasma phagocytophilum*, *Veterinary Parasitology*, 167 (2010), 108-22.

[34] L. Zhang, H. Liu, B. Xu, Q. Lu, L. Li, L. Chang, X. Zhang, D. Fan G. Jin, F. Cui, Y. Shi, W. Li, J. Xu, and X. Jie Yu, *Anaplasma phagocytophilum* infection in domestic animals in ten provinces, China, *The American Journal of Tropical Medicine and Hygiene*, 87 (2012), 185-189.

TABLE 1. SIGNALMENT, CLINICAL SIGNS AND CONCURRENT CONDITIONS OBSERVED IN 15 DISEASED DOGS DIAGNOSED WITH CANINE GRANULOCYTIC ANAPLASMOSIS IN DUBAI, BETWEEN 2010 AND 2013

N.	Breed	Sex	Age (years)	Clinical Signs	Associated conditions
1	St. Bernard	M	10	Lethargy, alopecia	Benign Papilloma
2	Pitt Bull	F	6	Lethargy, severe weakness, limping	Adult-onset generalized demodicosis
3	W-H Terrier	F	7	Blood in the urine, polydipsia, limping	Adult-onset generalized demodicosis
4	Chihuahua	M	1	Itching chronic dermatitis	A-OG Demodicosis and <i>Malassezia</i>
5	Chihuahua	M	8	1-year chronic cough, limping	Ringworm
6	En. Bulldog	M	3	1-month itching dermatitis	Adult-onset generalized demodicosis
7	Labrador R.	M	4	Fever, recurring dermatitis on abdomen	Pyoderma and Ringworm
8	Saluki	F	1	Fever, tick infestation, dermatitis	Pyoderma and Ringworm
9	G. Retriever	M	2	Limping, lethargy	-----
10	Shi-Tzu	M	6	Conjunctivitis, 3 seizures in a month	Mast Cell Tumor grade 1 in the paw
11	Yorkshire	F	2	Fever, lethargy, anorexia, vomiting, ticks infestation	<i>Malassezia</i> yeast dermatitis
12	Dachshund	F	3	Fever, lethargy, vomiting, skin hyperesthesia	-----
13	Dachshund	M	4	Fever, vomiting	-----
14	Boxer	M	2	Blood in the urine, lethargy, ticks infestation, pallid mucous membranes	-----
15	Fr.Bulldog	M	1	2-months itching dermatitis,	Adult-onset generalized demodicosis

TABLE 2. ANEMIA AND CELLULAR IMMUNOSUPPRESSION OBSERVED BEFORE (B.F.) BUT NOT AFTER THERAPY (A.T.) AGAINST CANINE GRANULOCYTIC ANAPLASMOSIS IN 15 DOGS EXAMINED IN DUBAI

	PCV		WBC		Neutrophiles		Lymphocytes		Thrombocytes	
	(37-55%)		(5500-16900/ μ L)		(2000-12000/ μ L)		(500-4900/ μ L)		(17500-500000/ μ L)	
	B.T.	A.T.	B.T.	A.T.	B.T.	A.T.	B.T.	A.T.	B.T.	A.T.
1	34.1	45.2	2480	5600	1560	3380	470	1320	30000	256000
2	32.7	50.1	1740	14610	1114	9010	480	3250	62000	266000
3	47.3	52.1	4430	9110	940	5860	2680	2320	136000	267000
4	43.4	44.2	280	12020	60	8970	210	1900	367000	505000
5	24.9	43.1	6029	15060	1990	9130	3580	4180	94000	494000
6	37.0	49.7	250	8980	100	4510	120	2930	43000	489000
7	21.5	46.8	480	5530	180	3140	290	1800	150000	176000
8	22.4	32.0	300	9840	60	4790	200	2700	73000	246000
9	23.2	37.1	340	14320	50	5240	260	3340	93000	232000
10	19.8	46.6	290	7080	50	3150	190	2320	83000	552000
11	47.2	52.4	310	7900	40	3290	220	2750	95000	310000
12	27.5	56.5	430	7930	120	4630	290	2350	138000	234000
13	60.1	58.3	4320	12340	1790	8630	1420	2320	456000	685000
14	23.3	44.8	6040	8810	1970	3680	2410	2650	70000	298000
15	45.1	57.3	5320	9310	1930	5130	2680	2640	45000	212000

Received: July 25, 2013